Dianthus Therapeutics reported earnings of -$ 0.81 per DNTH share on Nov 5, 2026, falling short of analysts' expectations by
| Report Date | Nov 5, 2026 |
|---|---|
| Forecasted EPS | -$ 0.94 |
| Earnings Per Share (Surprise) | -$ 0.81 (+$ 0.1345) |
| Last Year's EPS | -$ 1.03 |
| EPS YoY Change |
Out of the last 42 earnings reporting periods, Dianthus Therapeutics beat analysts’ expectations 11 times and fell short of expectations 11 time(s). Dianthus Therapeutics reported earnings per share of -$ 0.81 in the last report surpassing an estimated EPS of -$ 0.94 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 5, 2026 | -$ 0.94 | -$ 0.81 | -$ 1.43 | |
| Nov 4, 2026 | -$ 0.94 | -$ 0.81 | -$ 0.97 | |
| Aug 4, 2026 | -$ 0.85 | -$ 0.90 | -$ 0.88 | |
| May 5, 2026 | -$ 1.17 | -$ 0.85 | -$ 0.82 | |
| Mar 9, 2026 | -$ 0.98 | -$ 1.43 | -$ 0.81 | |
| Nov 5, 2025 | -$ 0.86 | -$ 0.97 | -$ 0.74 | |
| Aug 7, 2025 | -$ 0.86 | -$ 0.88 | -$ 0.51 | |
| May 12, 2025 | -$ 0.86 | -$ 0.82 | -$ 0.54 | |
| Mar 11, 2025 | -$ 0.85 | -$ 0.81 | -$ 0.71 | |
| Nov 7, 2024 | -$ 0.59 | -$ 0.74 | -$ 3.78 | |
| Aug 8, 2024 | -$ 0.55 | -$ 0.51 | -$ 3.12 | |
| May 9, 2024 | -$ 0.43 | -$ 0.54 | -$ 7.52 | |
| Mar 21, 2024 | -$ 1.11 | -$ 0.71 | -$ 7.70 | |
| Nov 9, 2023 | -$ 0.51 | -$ 3.78 | -$ 2.67 | |
| Aug 3, 2023 | -$ 0.80 | -$ 3.12 | -$ 4.32 | |
| May 15, 2023 | -$ 6.40 | -$ 7.52 | -$ 2.10 | |
| Mar 30, 2023 | -$ 6.40 | -$ 7.70 | -$ 4.64 | |
| Dec 31, 2022 | -$ 4.10 | -$ 2.67 | -$ 6.24 | |
| Nov 3, 2022 | -$ 4.64 | -$ 4.32 | -$ 5.25 | |
| Sep 30, 2022 | -$ 4.64 | -$ 2.10 | -$ 4.76 |
Dianthus Therapeutics’s stock was trading at $ 85.81 on Nov 4, 2026 a day before the last earnings report was released.Following the release of the earnings report, DNTH’s price increased to $ 86.03 on Nov 6, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 5, 2026 | -$ 0.81 | $ 85.81 | $ 86.03 | |
| Nov 4, 2026 | -$ 0.81 | $ 82.70 | $ 83.01 | |
| Aug 4, 2026 | -$ 0.90 | $ 106.02 | $ 112.50 | |
| May 5, 2026 | -$ 0.85 | $ 89.34 | $ 90.42 | |
| Mar 9, 2026 | -$ 1.43 | $ 65.20 | $ 86.92 | |
| Nov 5, 2025 | -$ 0.97 | $ 33.20 | $ 36.43 | |
| Aug 7, 2025 | -$ 0.88 | $ 20.39 | $ 18.76 | |
| May 12, 2025 | -$ 0.82 | $ 19.59 | $ 18.84 | |
| Mar 11, 2025 | -$ 0.81 | $ 24.34 | $ 21.90 | |
| Nov 7, 2024 | -$ 0.74 | $ 29.41 | $ 29.06 | |
| Aug 8, 2024 | -$ 0.51 | $ 25.80 | $ 27.50 | |
| May 9, 2024 | -$ 0.54 | $ 23.81 | $ 24.29 | |
| Mar 21, 2024 | -$ 0.71 | $ 27.10 | $ 31.94 | |
| Nov 9, 2023 | -$ 3.78 | $ 11.37 | $ 11.50 | |
| Aug 3, 2023 | -$ 3.12 | $ 12.91 | $ 12.80 | |
| May 15, 2023 | -$ 7.52 | $ 10.16 | $ 10.87 | |
| Mar 30, 2023 | -$ 7.70 | $ 12.48 | $ 12.72 | |
| Dec 31, 2022 | -$ 2.67 | $ 6.32 | $ 6.56 | |
| Nov 3, 2022 | -$ 4.32 | $ 19.68 | $ 19.20 | |
| Sep 30, 2022 | -$ 2.10 | $ 22.40 | $ 22.08 |
Dianthus Therapeutics released its most recent earnings reports in November 2026, November 2026, August 2026, May 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Dianthus Therapeutics beat analysts’ expectations during the last earnings period by
